InflaRx to Present Phase 3 Vilobelimab Data in Pyoderma Gangrenosum at AAD 2026
Event summary
- InflaRx's Phase 3 vilobelimab data for pyoderma gangrenosum selected for late-breaking oral presentation at AAD 2026.
- Presentation scheduled for March 28, 2026, in Denver, CO, by Benjamin Kaffenberger, MD.
- Vilobelimab is an anti-C5a monoclonal antibody targeting chronic immuno-inflammatory diseases.
- InflaRx also developing izicopan (INF904) for hidradenitis suppurativa and other inflammatory conditions.
The big picture
InflaRx's presentation at AAD 2026 highlights the growing focus on targeted complement system inhibition in dermatology. The company's dual approach with vilobelimab (intravenous) and izicopan (oral) positions it competitively in the immuno-inflammatory disease market, though success will depend on differentiating clinical outcomes and regulatory approval timelines. The Phase 3 data could be a pivotal milestone in validating the C5a/C5aR inhibition strategy.
What we're watching
- Clinical Efficacy
- Whether vilobelimab's Phase 3 results demonstrate sufficient efficacy to position it as a leading treatment for pyoderma gangrenosum.
- Regulatory Pathway
- The pace at which InflaRx can advance vilobelimab through regulatory approvals following positive Phase 3 data.
- Market Differentiation
- How InflaRx will position vilobelimab against existing and emerging therapies in the chronic immuno-inflammatory disease space.
Our editorial coverage: